Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
Rattachement africain : ro. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone of hematologic malignancy treatment, but it is limited by its dose-dependent cardiotoxicity, leading to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as a subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive and therapeutic strategies to reduce cancer therapy-related cardiac dysfunction (CTRCD). Current approaches, including beta-blockers, renin-angiotensin system (RAS) inhibitors, and statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, including reduced oxidative stress, inflammation, and myocardial remodeling. This review explores the interplay between anthracycline therapy, particularly DOX, and cardiotoxicity while evaluating SGLT2 inhibitors as novel agents in cardio-oncology. Preclinical studies suggest SGLT2 inhibitors attenuate CTRCD by preserving mitochondrial function and inhibiting apoptosis, while clinical trials highlight their efficacy in reducing heart failure (HF) hospitalizations and cardiovascular (CV) mortality. Integrating SGLT2 inhibitors into cardio-oncology protocols could revolutionize the management of CTRCD, enhancing patient outcomes in oncology and cardiovascular care. Considering the emerging evidence, SGLT2 inhibitors may provide significant benefits to patients undergoing anthracycline therapy, particularly those with elevated cardiovascular risk profiles. We recommend that future prospective, large-scale clinical trials further evaluate the efficacy and safety of these agents as cardioprotective therapy to optimize individualized treatment strategies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
- Date Crossref
- 03/05/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Victor Babeș University of Medicine and Pharmacy Timișoara pays non établi dans la noticeUniversité ou école supérieure
-
Polytechnic University of Timişoara pays non établi dans la noticeUniversité ou école supérieure
-
Spitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara pays non établi dans la noticeÉtablissement de santé
-
“Victor Babes” University of Medicine and Pharmacy Advanced Cardiology and Hemostaseology Research Center pays non établi dans la noticeUniversité ou école supérieure
-
University Clinic of Clinical Skills Department I of Nursing pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Emergency County Hospital “Pius Brinzeu” Timisoara Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen pays non établi dans la noticeÉtablissement de santé
-
Faculty of Industrial Chemistry and Environmental Engineering pays non établi dans la noticeUniversité ou école supérieure
Victor Babeș University of Medicine and Pharmacy Timișoara, Polytechnic University of Timişoara et Spitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.